Actively Recruiting

Phase 3
Age: 22Years +
All Genders
ID07207369

A Multicenter, Double-blind, Randomized Study to Evaluate Safety and Effectiveness of ELAPR002f Injectable Gel in Adults With Atrophic Acne Scars

Led by AbbVie · Updated on 2025-11-24

395

Participants Needed

10

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to evaluate the safety and effectiveness of ELAPR002f injectable gel in adults with moderate to severe atrophic acne scars. These scars are flat or indented marks that remain after acne heals and can affect quality of life through reduced self-esteem and embarrassment. The study is a controlled, randomized trial including about 395 adults with scarring on both cheeks, conducted at multiple sites in the United States. Participants are divided into two cohorts. Cohort 1 receives ELAPR002f injectable gel openly, while Cohort 2 participants are randomly assigned to receive either ELAPR002f gel or a saline control via intradermal injections. Treatments are given on Days 1, 31, and 61. After the three treatment sessions over two months, participants are followed for up to 12 months to observe outcomes and any side effects. During the study, participants will have regular visits at a clinic or hospital for medical assessments, blood tests, and questionnaires to monitor their progress and any side effects. Researchers will measure the percentage of participants who achieve at least a 20% reduction in acne scar area and various safety parameters, including injection site responses and changes in vital signs and laboratory values. The total study duration for each participant can be up to 420 days.

CONDITIONS

Brief Title

A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

Who Can Participate

Age: 22Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must be in generally good health and seeking improvement of atrophic acne scars.
  • Moderate to severe atrophic acne scarring (Grade 4 or 5 on the Allergan Acne Scar Improvement Scale) on both cheeks.
  • At least 5 rolling or boxcar-type acne scars within a 4 cm by 4 cm area on either cheek with otherwise healthy skin.
Not Eligible

You will not qualify if you...

  • Presence of clinically significant active acne on the face.
  • Current inflammatory or infectious skin conditions on the face other than acne, including herpes, rosacea, abscess, unhealed wounds, or cancerous/pre-cancerous lesions.
  • Predominantly ice pick type acne scars.
  • History of keloid or hypertrophic scarring, or post-inflammatory pigmentation changes (hyperpigmentation or hypopigmentation).

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Approximately 2 months

Participants receive intradermal injections of ELAPR002f Injectable Gel or saline control on Days 1, 31, and 61 to treat atrophic acne scars.

3 treatment visits (in-person)

Long-term Monitoring

Duration - Up to 420 days

Participants are followed for safety and effectiveness assessments after treatment.

Multiple follow-up visits over 14 months

Trial Site Locations

Total: 10 locations

1

Advanced Research Associates - Glendale /ID# 254961

Glendale, Arizona, United States, 85308

Actively Recruiting

2

Marcus Facial Plastic Surgery /ID# 275880

Redondo Beach, California, United States, 90277

Actively Recruiting

3

Pacific Clinical Innovations /ID# 256185

Vista, California, United States, 92083-6030

Actively Recruiting

4

DMR Research PLLC /ID# 256199

Westport, Connecticut, United States, 06880

Actively Recruiting

5

Hamilton Research, LLC /ID# 256925

Alpharetta, Georgia, United States, 30022

Actively Recruiting

6

Aesthetic Center at Woodholme /ID# 256197

Baltimore, Maryland, United States, 21208-6391

Actively Recruiting

7

The Center for Dermatology Cosmetics & Laser Surgery /ID# 256182

Mount Kisco, New York, United States, 10549-3028

Actively Recruiting

8

Wilmington Dermatology Center /ID# 256192

Wilmington, North Carolina, United States, 28403

Actively Recruiting

9

Austin Institute for Clinical Research - Pflugerville /ID# 256200

Pflugerville, Texas, United States, 78660

Actively Recruiting

10

SkinDC /ID# 254962

Arlington, Virginia, United States, 22209

Actively Recruiting

Loading map...

Research Team

A

ABBVIE CALL CENTER

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here